ANI Pharmaceuticals Inc

ANIP is in a Stage 4 decline with supply dominating demand and price trading below all declining EMAs and SMAs. Both medium- and short-term biases are firmly bearish, with no exhaustion or reversal patterns evident despite extreme oversold readings. Execution is recommended now by selling into the nearby resistance zone around the 9/20 EMAs and the 50 SMA.

• ↑Q2 net revenue $266M (+25.9% YoY) led by Cortrophin Gel
• ↑Rare disease sales rose 30.7% to $135.8M
• ↓Mgmt cut full-year Cortrophin Gel revenue guidance to $520–540M